Age and frailty should be considered independently when evaluating potential risk for side effects among older adults treated with ICIS

 Researchers at the Princess Margaret Cancer Centre in Toronto recently released the findings of a population-level retrospective cohort study aimed at evaluating "the impact of age and frailty among older adults on use of acute care and immune-related adverse events (irAE) associated hospitalizations."  According to Dr. Lawson Eng of the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre, older age carried a lower risk of being hospitalized due to irAE, particularly those over the age of 80, which constituted 18% of the 2737 patients who participated in the study.  The study concluded that age and frailty are significant associated factors which "may need to be considered independently when evaluating their use [in] influencing risk of toxicity among older adults receiving ICIs." 

To read more about this study, click here. 

Source mentioned: Eng L, Sutradhar R, Kaliwal Y, et al. Impact of age and frailty on acute care use during immune checkpoint inhibitor (ICI) treatment: A population-based study. J Clin Oncol 2022; 40 (suppl 16; abstr 12002). DOI: 10.1200/JCO.2022.40.16_suppl.12002